Is It Time To Reassess Doximity (DOCS) After Its 65% One Year Share Price Slide

Simply Wall St.

Feb 24

If you are wondering whether Doximity is starting to look like value or is still priced for high expectations, you are in the right place to assess what the current share price really reflects. The ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2613732544"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2613732544\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2613732544?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574","is_english":true,"pubTime":"2026-02-24 03:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613732544","market":"sg","top_or_hot":-1,"title":"Is It Time To Reassess Doximity (DOCS) After Its 65% One Year Share Price Slide","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Doximity is starting to look like value or is still priced for high expectations, you are in the right place to assess what the current share price really reflects. The ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-docs/doximity/news/is-it-time-to-reassess-doximity-docs-after-its-65-one-year-s\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time To Reassess Doximity (DOCS) After Its 65% One Year Share Price Slide</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time To Reassess Doximity (DOCS) After Its 65% One Year Share Price Slide\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-24 03:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-docs/doximity/news/is-it-time-to-reassess-doximity-docs-after-its-65-one-year-s><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Doximity is starting to look like value or is still priced for high expectations, you are in the right place to assess what the current share price really reflects. The ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-docs/doximity/news/is-it-time-to-reassess-doximity-docs-after-its-65-one-year-s\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DOCS","symbol_name":"Doximity, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-docs/doximity/news/is-it-time-to-reassess-doximity-docs-after-its-65-one-year-s","article_id":"2613732544","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-docs/doximity/news/is-it-time-to-reassess-doximity-docs-after-its-65-one-year-s","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2613732544","pubTimestamp":1771875086,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Doximity is starting to look like value or is still priced for high expectations, you are in the right place to assess what the current share price really reflects.\nThe stock most recently closed at US$25.55, after a 2.1% move over the past week, but with much steeper returns of a 37.1% decline over 30 days, a 41.0% decline year to date, and a 64.7% decline over the past year.\nThese sharp price moves have come alongside ongoing discussion about Doximity's role as...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DOCS":"Doximity, Inc.","BK4613":"AI应用软件","BK4167":"医疗保健技术","BK4588":"碎股","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4551":"寇图资本持仓","BK4539":"次新股","BK4585":"ETF&股票定投概念"},"translate_title":"Doximity(DOCS)股价一年下跌65%后，是时候重新评估它了吗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"DOCS":1.5},"content_text":"If you are wondering whether Doximity is starting to look like value or is still priced for high expectations, you are in the right place to assess what the current share price really reflects. The stock most recently closed at US$25.55, after a 2.1% move over the past week, but with much steeper returns of a 37.1% decline over 30 days, a 41.0% decline year to date, and a 64.7% decline over the past year. These sharp price moves have come alongside ongoing discussion about Doximity's role as a digital platform for healthcare professionals and how that position fits into investors' appetite for growth-focused software names. Recent commentary has focused on whether the current share price still embeds high growth expectations or whether sentiment has reset enough to make valuation the main story. On our simple 6 point valuation framework, Doximity currently scores a 5 out of 6, which suggests it screens as undervalued on most of the checks we run. Next, we will walk through different valuation approaches before finishing with an even richer way to think about what the stock might be worth over time.  Find out why Doximity's -64.7% return over the last year is lagging behind its peers. AdvertisementApproach 1: Doximity Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow model takes the cash Doximity is expected to generate in the future and discounts those projections back into today’s dollars to estimate what the whole business could be worth right now. Doximity’s latest twelve month free cash flow is about $306.6 million. Using a 2 Stage Free Cash Flow to Equity model, analysts and extrapolations project free cash flow reaching around $447.4 million by 2030, with a detailed path laid out from 2026 through 2035 based on a mix of analyst inputs and growth estimates. All of these future cash flows are converted into present values and summed. On this basis, the model arrives at an estimated intrinsic value of about $48.13 per share. Compared with the recent share price of US$25.55, the DCF implies the stock trades at a 46.9% discount to that estimate. This indicates a meaningful gap between the modeled value and the current market price. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Doximity is undervalued by 46.9%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks. DOCS Discounted Cash Flow as at Feb 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Doximity. Approach 2: Doximity Price vs Earnings For profitable companies, the P/E ratio is a useful way to think about valuation because it links what you pay today directly to the earnings the business is already producing. In general, higher expected growth and lower perceived risk can support a higher P/E, while slower growth and higher risk usually justify a lower one. Doximity currently trades on a P/E of 19.71x. That sits below the Healthcare Services industry average P/E of 29.50x and also below the peer group average of 49.58x, which suggests the market is attaching a lower earnings multiple to Doximity than to many comparable names. Simply Wall St’s Fair Ratio for Doximity is 19.98x. This is a proprietary estimate of what a reasonable P/E could be for the company given its earnings growth profile, industry, profit margins, market capitalization and risk factors. Because it is tailored to Doximity’s own characteristics rather than broad groups, the Fair Ratio can be more informative than a simple comparison with peers or the sector. With the current P/E of 19.71x sitting very close to the Fair Ratio of 19.98x, the multiple suggests the shares are priced roughly in line with these fundamentals. Result: ABOUT RIGHT NYSE:DOCS P/E Ratio as at Feb 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 22 top founder-led companies. Upgrade Your Decision Making: Choose your Doximity Narrative Earlier we mentioned that there is an even better way to understand valuation. Let us introduce you to Narratives, a simple tool on Simply Wall St's Community page that helps you turn your view of Doximity into a clear story linked to a forecast and a Fair Value. You can compare this Fair Value with the current share price, and it then updates automatically when fresh news or earnings arrive. For example, one investor might align with a cautious Doximity Narrative built around a Fair Value near US$25, softer revenue growth assumptions, lower profit margins and a lower future P/E. Another might choose a more optimistic Narrative that leans toward a Fair Value closer to about US$69, higher expected revenue growth, stronger margins and a higher future P/E. By putting your own assumptions on the same footing, Narratives give you a straightforward way to decide whether the current price looks high, low, or about right for the story you believe. For Doximity however, we will make it really easy for you with previews of two leading Doximity Narratives: On Simply Wall St, each Narrative ties a story about the business to a set of explicit assumptions and a Fair Value, so you can quickly see which version of the future feels closer to your own view and whether the current US$25.55 share price looks high, low, or somewhere in the middle. 🐂 Doximity Bull Case Fair value: US$63.57 Implied discount to this Fair Value vs US$25.55: about 59.8% undervalued using ((63.57 - 25.55) / 63.57) Revenue growth assumption: 10.16% a year  Views Doximity as a high quality healthcare platform with strong clinician engagement, expanding AI tools and workflow features that could support long term revenue and margin strength. Sees digital healthcare marketing demand, health system adoption and AI driven efficiency as supportive of relatively stable earnings and solid free cash flow, even while the company spends on growth. Accepts risks such as heavy pharma exposure, regulatory changes, AI monetization timing and stock based compensation, but still concludes that a Fair Value around US$63.57 is reasonable under these assumptions.  🐻 Doximity Bear Case Fair value: US$25.00 Implied premium to this Fair Value vs US$25.55: about 2.2% overvalued using ((25.55 - 25.00) / 25.00) Revenue growth assumption: 6.91% a year  Starts from the most cautious analyst inputs, with slower revenue growth, lower margins and a lower future P/E, which together point to a Fair Value of about US$25.00, close to the current share price. Emphasizes risks around regulation, tighter digital marketing budgets, competition from larger health IT platforms, and the possibility that Doximity is treated as a non essential add on rather than a must have system. Still acknowledges strong engagement, cash generation, AI tools and buybacks as supports for the business, but treats them as not enough to justify paying far above the low case Fair Value on these assumptions.  If you want to pressure test which of these stories feels closer to your own view, you can read them in full on Simply Wall St and then adjust the levers like growth, margins, and future P/E until the Fair Value feels aligned with your expectations. Curious how numbers become stories that shape markets? Explore Community Narratives Do you think there's more to the story for Doximity? Head over to our Community to see what others are saying! NYSE:DOCS 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}